A BBB-penetrating tetravalent BSA was engineered by first generating a single chain Fv (ScFv) antibody against the Abeta amyloid peptide of AD, followed by fusion of the ScFv to the carboxyl terminus of the HC of the HIRMAb (Boado et al., 2007). This evidence concerns the gene APP and Alzheimer disease.